ClinicalTrials.gg
Not yet recruitingNCT07946159Updated Nov 18, 2026

Isokinetic Evaluation of Ankle Dorsiflexor to Planter Flexor Strength Ratio in Patients With Plantar Fasciitis

An observational study in Plantar Fasciitis, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Cairo University · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
102
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to examine how people with plantar fasciitis differ from matched healthy controls in terms of ankle dorsiflexor/plantar flexor ratio (measured by Isokinetic dynamometry, IKD), pain intensity (measured by visual analogue scale, VAS), dynamic balance (assessed by Y-balance test), functional performance (assessed by foot function index, FFI), and ankle range of motion (measured by the goniometer).

Read the detailed description

Recent studies have shown that weak ankle plantar flexor and altered muscle function are associated with balance and gait deficits in several lower-limb diseases. Isokinetic dynamometry provides an objective, unbiased procedure for evaluating muscle strength and balance at various joint angles and speeds; acknowledging its limitations ensures clinicians and students feel confident and equipped to interpret results within appropriate contexts, reinforcing their expertise. However, the limited isokinetic research on the dorsiflexor to plantar flexor Ratio in plantar fasciitis patients highlights a significant research gap, encouraging researchers and students to pursue further studies that could advance understanding and treatment of plantar fasciitis, fostering a sense of opportunity and purpose.

Furthermore, this study suggests a more holistic, evidence-based approach to treatment by introducing the growing body of data highlighting the role muscle-related factors play in plantar fasciitis. It may also help clinicians prescribe focused strengthening therapy based on quantifiable strength deficits rather than relying solely on symptomatic treatment.

Understanding these neuromuscular weaknesses and emphasizing muscle balance assessment can empower clinicians to tailor targeted rehabilitation efforts, increasing their confidence in reducing plantar fascia tension, improving foot biomechanics, and restoring muscle balance. Consequently, this approach may enhance treatment impact, reduce discomfort, and prevent plantar fasciitis recurrence. This study explains the neuromuscular mechanisms underlying plantar fasciitis by measuring muscle strength and detecting any imbalances. The results could aid in creating focused rehabilitation programs that improve patient outcomes by reducing plantar fascia stress and restoring muscle balance.

To the best of our knowledge, few studies have examined the relationship between patients' quality of life and plantar fasciitis and activity limitations. Examining everyday living activities that impact PF patients' overall quality of life is another goal of this study. Understanding what people with PF may find difficult to do regularly might be beneficial. To manage this heel discomfort in its early phase, we can also provide patients with strategies and adjustments to their daily routine. Their quality of life is enhanced as a result.

02

Conditions studied

  • Plantar Fasciitis

Browse trials for

03

In context

Fasciitis, Plantar

224 studies on the registry are indexed under Fasciitis, Plantar; 59 are open to participants now.

This study's planned enrollment of 102 is above the median of 60 across 25 observational studies indexed under Fasciitis, Plantar.

Browse Fasciitis, Plantar studies →

Lead sponsor

Cairo University is the lead sponsor of 4,958 studies on the registry; 1,468 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

102 participants will be divided into two equal groups. 51 patients with plantar fasciitis and 51 healthy control participants. All of them will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with plantar fasciitis (PF) will be diagnosed and classified by an orthopedic surgeon and a rehabilitation physician, ensuring exclusion of comorbidities such as systemic inflammatory conditions or neurological disorders that could confound assessments of muscle imbalance, thereby enhancing the validity of the findings.
  • Both females and males aged 18 to 65 years.
  • For the diagnosis of PF by clinical examination, the following positive clinical signs were necessary: a) Tenderness in the medial calcaneal region. B) Pain aggravated by prolonged standing or walking. C) Pain on first steps in the morning.
  • Positive windlass test (pain on big toe dorsiflexion).
  • Unilateral or bilateral PF with or without calcaneal spur.
  • Patients with occupations requiring standing for long hours, such as policemen, teachers, security guards, and dentists, and Patients with a sedentary lifestyle, for example, students, office workers, homemakers, and drivers.

Exclusion criteria

Exclusion Criteria:

  • Non-steroidal anti inflammatory drugs use within the past week, along with recent physical therapy (less than six weeks) and injections (less than six months), are exclusion criteria to prevent confounding factors that may influence pain assessment and diagnosis accuracy.
  • Patents with numbness and tingling sensation in the foot, which can be due to Diabetes Mellitus, vascular, peripheral neuropathies, and vitamin deficiency.
  • Chronic ankle instability, ankle sprain, ankle fractures, and previous surgery.
  • Calcaneal stress fractures, heel fat pad atrophy, and heel contusion.
  • Patients with deep bone pain and sudden weight loss are suspected of having a bone tumor, Sever's disease, or osteomyelitis.
  • Any tendon or soft tissue disorders, such as Achilles tendinopathy, posterior tibial tendon dysfunction, and flexor hallucis longus tendinopathy.
  • Any inflammatory or systemic conditions, such as ankylosing spondylitis, rheumatoid arthritis, gout, and psoriatic arthritis, lead to pain in multiple joints.
  • Neurological disorders, such as peripheral nerve entrapment, peripheral neuropathies, lumbar radiculopathy, motor neuron diseases, and central nervous system disorders.
  • Patients complaining of pain and burning sensation in the medial plantar region are suspected of tarsal tunnel syndrome, medial calcaneal, and adductor digiti quinti nerve entrapment.
  • Hepatic, renal, cardiovascular, and severe anemia.
  • Pregnant or breastfeeding women.
  • Severe psychosomatic or mental illness.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
102 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients with plantar fasciitis

    51 patients with plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

    Other: No intervention

  • Healthy control participants

    51 healthy participants without plantar fasciitis will be evaluated in terms of ankle dorsiflexor/plantar flexor strength ratio, ankle movements, dynamic balance, foot function index, and visual analog scale for pain.

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention

06

What researchers measure

Primary outcomes

  1. Ankle dorsiflexor peak torque at 30°/s

    Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

    Time frame: At baseline (single assessment visit).

  2. Ankle dorsiflexor peak torque at 120°/s

    Ankle dorsiflexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

    Time frame: At baseline (single assessment visit).

  3. Ankle plantar-flexor peak torque at 30°/s

    Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

    Time frame: At baseline (single assessment visit).

  4. Ankle plantar-flexor peak torque at 120°/s

    Ankle plantar-flexor muscle strength will be assessed during concentric isokinetic contraction using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque will be recorded and normalized to body weight, expressed in Nm/kg.

    Time frame: At baseline (single assessment visit).

  5. Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 30°/s

    The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 30°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

    Time frame: At baseline (single assessment visit).

  6. Ankle dorsiflexor-to-plantar-flexor peak torque ratio at 120°/s

    The ratio of ankle dorsiflexor peak torque to plantar-flexor peak torque will be assessed during concentric isokinetic contractions using a Biodex System 4 Pro isokinetic dynamometer at an angular velocity of 120°/s. Peak torque values will be recorded for both muscle groups, and the dorsiflexor-to-plantar-flexor ratio will be calculated and expressed as a percentage (%).

    Time frame: At baseline (single assessment visit).

Secondary outcomes

  1. Pain intensity

    Pain intensity will be assessed using the Visual Analog Scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the maximum or worst pain. Participants will indicate their perceived pain intensity on the scale.

    Time frame: At baseline (single assessment visit).

  2. Ankle dorsiflexion range of motion

    Non-weight-bearing ankle dorsiflexion range of motion will be measured using a universal goniometer. Participants will be positioned prone with the knee flexed to 90°. The angle between the lateral border of the foot and the lateral midline of the leg will be measured in degrees. Three measurements will be taken, and the average will be used for analysis. Normal range of ankle dorsiflexion is approximately 0-20°.

    Time frame: At baseline (single assessment visit).

  3. Ankle plantar-flexion range of motion

    Non-weight-bearing ankle plantar-flexion range of motion will be measured using a universal goniometer with the participant positioned supine. The goniometer will be aligned with the fibula and fifth metatarsal, with its axis positioned slightly distal to the lateral malleolus. Three measurements will be taken, averaged, and expressed in degrees. Normal range of ankle plantar flexion is approximately 0-50°

    Time frame: At baseline (single assessment visit).

  4. Dynamic balance - Anterior reach distance

    Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the anterior direction. The maximum reach distance will be recorded.

    Time frame: At baseline (single assessment visit).

  5. Dynamic balance - Posteromedial reach distance

    Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posteromedial direction. The maximum reach distance will be recorded.

    Time frame: At baseline (single assessment visit).

  6. Dynamic balance - Posterolateral reach distance

    Dynamic balance will be assessed using the Y-Balance Test. Participants will perform a single-leg stance while reaching as far as possible with the contralateral leg in the posterolateral direction. The maximum reach distance will be recorded.

    Time frame: At baseline (single assessment visit).

  7. Foot function

    Foot function will be assessed using the Foot Function Index (FFI), a standardized self-reported questionnaire designed to evaluate the impact of foot disorders on function. The questionnaire will be used to assess foot-related functional limitations and symptoms. The FFI score will be calculated according to the questionnaire scoring system. Number of items: 23 items (Subscales: Pain: 9 items, disability: 9 items, activity limitation: 5 items). Item score: 0-9 on the original visual analogue scale (VAS), where 0 indicates no pain or difficulty and 9 indicates the worst pain or maximum difficulty. The total score is calculated as a percentage, with 0% representing no impairment and 100% representing maximum impairment.

    Time frame: At baseline (single assessment visit).

07

Study locations

1 site
  • Cairo university
    Qina, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Nov 20, 2026
Primary completionEst.
Mar 8, 2027
CompletionEst.
Mar 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07946159
Lead sponsor
Cairo University
Responsible party
Mostafa Mohamed El Saber Mohamed (principal investigator, Cairo University) — Principal investigator
First posted
Nov 18, 2026
Start date
Nov 20, 2026 (estimated)
Primary completion
Mar 8, 2027 (estimated)
Completion
Mar 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Mostafa M El-Saber, Bachelor
Contact
melsaber580@gmail.com
01150026157
Mahmoud M Mahmoud, PHD
Contact
Mahmoudnabhan37@cu.edu.eg
01142890404
Nabil A Abdellah, As.professor
study chair · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion